Etalocib
Appearance
![]() | |
Names | |
---|---|
Preferred IUPAC name
25-Ethyl-14-fluoro-22-hydroxy-82-propyl-3,7,9-trioxa-1,10(1),2(1,4),8(1,3)-tetrabenzenadecaphane-102-carboxylic acid | |
Other names
LY293111
VML 295 | |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
KEGG | |
PubChemCID
|
|
UNII | |
CompTox Dashboard(EPA)
|
|
| |
| |
Properties | |
C33H33FO6 | |
Molar mass | 544.619g·mol−1 |
Except where otherwise noted, data are given for materials in theirstandard state(at 25 °C [77 °F], 100 kPa).
|
Etalocibis a drug candidate that was under development for the treatment of various types of cancer.[1]It acts as aleukotriene B4 receptorantagonistand aPPARγ agonist.[2]
Clinical trials were conducted measuring efficacy for treatment ofnon-small cell lung cancerandpancreatic cancerand the inflammatory conditionsasthma,psoriasis,andulcerative colitis,but were suspended due to lack of efficacy.[3]
References
[edit]- ^Jänne, P. A.; Paz-Ares, L; Oh, Y; Eschbach, C; Hirsh, V; Enas, N; Brail, L; von Pawel, J (2014)."Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer".Journal of Thoracic Oncology.9(1): 126–31.doi:10.1097/JTO.0000000000000037.PMID24346102.
- ^Adrian, T. E.; Hennig, R; Friess, H; Ding, X (2008)."The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer".PPAR Research.2008:827096.doi:10.1155/2008/827096.PMC2631651.PMID19190780.
- ^"Etalocib".Adisinsight.Retrieved31 January2017.